• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
healthcare providers

Ward Hagar, MD

Healthcare Provider
Adult Program Director, Comprehensive Center for Sickle Cell Disease
UCSF Benioff Children's Hospital
Main Hospital
747 52nd Street
Oakland, California, United States

Dr. Hagar is the Director of Adult Sickle Cell Program at the Comprehensive Center for Sickle Cell Disease. He provides adult hematology services for thalassemia center. His clinical specialties include sickle cell disease, thalassemia, apheresis, gene therapy, hemoglobinopathies, iron metabolism, statistics and pain management.

Dr. Ward manages hundreds of sickle cell patients both in the clinic, hospital transfusion unit, and in local hospitals, serving as the sickle cell consultant and resource for emergency departments and hospitalist groups at the UCSF Benioff Children’s Hospital, Oakland.

After completing both his Advanced Training in Clinic Research at UCSF and an NIH T32 clinical training program focusing on transfusional iron, he has been an investigator on numerous clinical trials involving sickle cell and thalassemia and their complications. He is actively involved in National Sickle Cell Policy.

Dr. Ward Hagar is a co-author of the Social Security Administration’s revision of disability criteria for sickle cell and other anemias and serves on protocol design committees for multicenter studies. He continues to work on aspects of adults with sickle cell disease, serving on the protocol design committee for multicenter studies for both pharmaceutical studies and NIH- funded trials.


Representative Publications:

Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial

Defining Sickle Cell Disease Mortality Using a Population-Based Surveillance System, 2004 through 2008

Teasing Apart Pain in Sickle Cell Disease

Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management

A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction


expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.